ксном Parkinson's Disease

Treatment approaches covered

Pharmacotherapy | Behavioral therapy | Exercise-based therapy | Deep brain stimulation | Infusion/injection-based delivery



Details

- 1 Includes cognitive impairment, hallucinations and psychosis, depressed mood, anxious mood, apathy, and features of dopamine dysregulation syndrome
- 2 Includes sleep problems, daytime sleepiness, pain and other sensations, urinary problems, constipation problems, light headedness on standing, fatigue, sweating, and sexual function
- 3 Includes speech, saliva and drooling, chewing and swallowing, eating tasks, dressing, hygiene, handwriting, doing hobbies and other activities, turning in bed, tremor, getting out of a bed, a car, or a deep chair, walking and balance, and freezing.
- 4 Recommended to track via the Parkinson's Disease Quality of Life Questionnaire (PDQ-8)


For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/Parkinsons-Disease

© 2023 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more Sets of Patient-Centered Outcome Measures. Version 4.0.0 Revised: January 2022


ICHOM Approach

The ICHOM Set is the result of hard work by a group of leading physicians, measurement experts and patients together with the non-profit organization ICHOM. It represents the outcomes that matter most to patients with Parkinson's disease. We urge all providers around the world to start measuring these outcomes to better understand how to improve the lives of the patients they serve.

The Process



The Working Group



Canada

Connie Marras | University of Toronto Germany

Richard Dodel | Philipps-Universität Marburg

Italy

Angelo Antonini | IRCCS San Camillo, Venice

Netherlands

Bas Bloem | Radboud University Nijmegen Medical Center

Spain

Pablo Martinez-Martin | National Center of Epidemiology and CIBERNED

Sweden

Peter Hagell | Kristianstad University

Per Odin | Skåne University HospitalPaul de Roos | Uppsala University Hospital

United Kingdom

K Ray Chaudhuri | King's College, London **United States**

Shyamal Mehta | Mayo Clinic Ryan Uitti | Mayo Clinic

Daniel Weintraub | Hospital of the University of Pennsylvania Bill Wilson* | Parkinson's Disease Foundation

*Patient representative